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Abstract 
Purpose: To evaluate the health-related quality of life (HRQoL) of patients taking different antiretroviral 
regimens. 
Methods: A cross-sectional descriptive design was used to evaluate HRQoL of patients on Highly 
Active Antiretroviral Therapy (HAART) at Usmanu Danfodiyo University Teaching Hospital (UDUTH), 
Sokoto, Nigeria. Data were collected using HIV/AIDS-Targeted Quality of Life instrument between May 
and November, 2015 from 872 adult outpatients who had been on their regimen for at least 6 months. 
Data were statistically analysed. 
Results: The overall HRQoL score of the patients was 59.40 ± 18.66. Among patients on the first-line 
regimens, those on TDF + FTC + EFZ (60.52 ± 19.17) and those on TDF + 3TC + EFZ (64.41 ± 18.04) 
reported the best HRQoL scores. The difference between the scores of patients on the two most utilised 
regimens; AZT + 3TC + NVP (58.14 ± 18.53) and TDF + 3TC + EFZ (64.41 ± 18.04) was significant (p < 
0.05). Among patients on second-line regimens, those on TDF + FTC + LPVr (67.58 ± 14.80) reported 
the highest HRQoL score. 
Conclusion: Patients in this facility had a moderate HRQoL. TDF + 3TC + EFZ, TDF + FTC + EFZ and 
TDF + FTC + LPVr were the regimens with the best HRQoL outcomes. The use of these regimens 
should be encouraged for better patient well-being. 
 
Keywords: HIV, Health-related quality of life, Antiretroviral therapy, First-line antiretroviral regimen, 
Second-line antiretroviral regimen 
 
This is an Open Access article that uses a funding model which does not charge readers or their institutions 
for access and distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative 
(http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly credited. 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




The global epidemic of human immunodeficiency 
virus (HIV), which affects the human immune 
system is alarming as the number of people 
living with HIV/AIDS (PLWHA) continues to 
increase annually [1,2]. As at the year 2010, 
Sub-Saharan Africa was the most heavily 
affected region with 68 and 66 % of all HIV cases 
and deaths respectively [3]. Nigeria has the 
second largest number of PLWHA, after South-
Africa, with 3.4 million in 2012 [4]. 
-----------------------------------------------------------------------------------------------------------------------------------------------------
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Even though the annual global incidence and 
AIDS-related death decrease gradually [1,2], the 
burden of lifelong antiretroviral therapy (ART) 
and the chronic nature of this disease could 
negatively affect the Health-Related Quality of 
Life (HRQoL) of PLWHA. Thus, antiretroviral 
(ARV) regimens that would provide the best 
outcome to the patients is required. 
 
Several studies were conducted on the clinical 
outcomes of ART with the aim of identifying the 
best course of managing PLWHA but only few 
were on the patients’ HRQoL (humanistic 
outcome). Unlike humanistic, the clinical 
outcomes are important in providing information 
about treatment progress but not always on 
patients’ wellbeing and prognosis [5,6]. Thus, 
patients’ HRQoL is increasingly preferred as the 
measure of patients’ outcome of therapy [7,8]. 
 
Studies comparing the HRQoL outcome of 
different ARV regimens appear to be few. 
Although, studies on the QoL of patients on 
different dosage forms of Lopinavir/ritonavir in 
monotherapy [9], and that of patients on 
efavirenz-based regimens, who were previourly 
on Protease inbibitor-based regimens [10] were 
conducted. Others were on the overall HRQoL of 
PLWHA receiving ART and the effects of 
sociodemographic and clinical variables 
[6,11,12]. 
 
Clinical outcomes of different ARV regimens 
were more studied. Some of those studies 
reported the superiority of some first-line 
regimens in terms of improvement, adverse 
effects or cost effectiveness [13-17].  
 
In this study, the HRQoL of patients taking 






The study was carried out at Usmanu Danfodiyo 
University Teaching Hospital, Sokoto (UDUTH). 
The hospital is a tertiary health facility located in 
the capital city of Sokoto State, North-western 
Nigeria. It offers health services to the residents 
of the State and serves as the referral centre to 
other states, especially the neighbouring Niger, 
Kebbi and Zamfara States. According to the 
health record department of the hospital, as at 
year 2014, the hospital has 700 beds capacity 
and an average of 850 daily outpatient 
attendance. Comprehensive HIV treatment and 










HIV-infected outpatients attending UDUTH were 
used for this study. 
 
Included in the study were all HIV positive adults 
(18 years and above) and have been on their 
current ART regimen for at least 6 months were 
included. All patients that could not meet the 
inclusion criteria or have declined treatment 
within the last 6 months were excluded for this 
study. 
 
Data collection instrument 
 
HIV/AIDS-Targeted Quality of Life (HAT-QoL) 
instrument is a QoL instrument specific to People 
Leaving with HIV/AIDS. It consists of 34 item 
stems in nine domains: overall function, health 
worries, life satisfaction, disclosure worries, 
financial worries, medication concerns, provider 
trust, HIV mastery and sexual function. 
 
The questionnaire was developed and validated 
by Holmes and Shea [18]. Its reliability has 
further been proven by its successful application 
in Africa in a study by Greeff et al [19] and two 
studies in Nigeria by Ekott et al [20] and Oparah 
et al [11]. 
 
Response to the questionnaire items were 
anchored on a 5-point scale: “All of the time”, “A 
lot of the time”, “Some of the time”, “A little of the 
time”, and “None of the time”, corresponding to 5, 
4, 3, 2 and 1 respectively. Negatively worded 
questions were reversed prior to analysis. The 
highest score (5) corresponded to best possible 
HRQoL and the lowest score (1) corresponded to 
worst possible HRQoL. 
 
Data collection procedure 
 
All patients who gave their consent and attended 
clinic within the study period were studied. 
Patients’ sociodemographic characteristics, 
clinical as well as their medication data were 
collected from their folders using a data 
collection form. Data on patients’ HRQoL were 
gathered by using the HIV/AIDS- Targeted 
Quality of Life (HAT-QoL) instrument. A total of 
872 outpatients who attended clinic within the 
period of May and November, 2015 were 
evaluated. 
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Ethical considerations  
 
The ethical approval for this study was obtained 
from the Ethical Committee of the Usmanu 
Danfodiyo University Teaching Hospital, Sokoto 
(no. UDUTH/HREC/2014/No.279). The data 
collection procedure was in accordance with the 
ethical standards of World Medical Association 
Declaration of Helsinki [21]. Oral and written 
consent was obtained from each participant and 
they were assured of the confidentiality of the 




Data coding and scoring 
 
Responses from the questionnaire were coded 
and entered into a Microsoft Excel spread sheet 
2013 version and then imported into Statistical 
Product and Service Solutions (SPSS) version 
20.0 for analysis. The coding was done in two 
ways, depending on the nature of the question in 
the questionnaire. For positively worded 
questions, “All of the time” to “None of the time” 
responses were scored 5 to 1 respectively. While 
for the negatively worded ones, “All of the time” 
to “None of the time” responses were scored 1 to 
5, respectively. 
 
Table 1: Scoring system 
 
Domain  Scoring formula 
Overall function: OVFXN100 = (100/(30-6)) × 
(OVFXN- 6) 
Life satisfaction: LISAT100 = (100/(20- 4)) × 
(LISAT-4)  
Health worries: HEAWO100 = (100/(20-4)) × 
(HEAWO- 4) 




MEDWO100 = (100/(25 - 5)) × 
(MEDWO-5) 
HIV mastery: HIVMA100 = (100/(10-2)) × 
(HIVMA-2)  
Disclosure worries: DISWO100 = (100/(25-5)) × 
(DISWO-5) 
Provider trust: PROTR100 = (100/(15-3)) × 
(PROTR-3)  





34)) × (SXFXN-34) 
 
All HAT-QoL domains were scored and the final 
domain score was transformed into a linear 0 to 
100 scale where 0 represented the worst score 
possible and 100 the best score possible. The 
total score of items, within each domain was 
used to calculate the domain score (on a 0 to 
100 scale). Similarly, the overall domain scores 
were used to calculate the overall HRQoL score 
of the patients. The scoring system is shown 
Table 1. 
 
Finally, the overall HRQoL scores of the patients 
were classified into “Low HRQoL”, “Moderate 
HRQoL” and “High HRQoL” for patients with “0 to 





The sociodemographic and clinical 
characteristics, the distribution of antiretroviral 
regimens used as well as HRQoL scores of the 
population were analysed using descriptive 
statistics. The difference in the frequency 
distribution of categorised HRQoL scores and 
ARV regimens used in the facility was tested 
using Chi square. Difference between the 
HRQoL scores of patients taking some ARV 
regimens used in the facility was tested using 
Students’ T-test. Confidence interval was set at 





Sociodemographic and clinical characteris-
tics of the patients  
 
Among the 872 patients studied (Table 2), 651 
(75.9 %) of them were female. On their 
educational level, those with no formal education 
254 (29.8 %) were the highest followed by those 
with post-secondary education 227 (26.6 %). 
Most of the patients were married 471 (59.8 %), 
with less than 250.00 USD earnings per month 
590 (91.1 %). On the average, their family size 
and age were 7.06 ± 5.72 and 35.68 ± 9.41 
respectively. 
 
The clinical characteristics of the patient with 
respect to duration (years) of HIV diagnosis, 
years on ART and years on the current ART 
regimen was 5.25 ± 3.07, 4.93 ± 3.00 and 3.83 ± 
2.43, respectively. Their mean CD4 count and 
body weight were 458.59 ± 258.3 and 64.30 ± 
14.48, respectively. Predominantly, the patients 
had greater than 95 % adherence – 425 (84 %) 
and were on WHO clinical stage one 451 (58.4 
%). 
 
About 45.8 % (399 out of 872) of the patients had 
at least one co-morbidity. The patients mostly 
suffer from malaria (46.87 %), then body pains 
(11.78 %), hypertension (10.03 %) and peptic 
ulcer disease (9.77 %). 
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Overall HRQoL of patients receiving antire-
troviral therapy  
 
The mean overall HRQoL score was 59.4 (table 
3). According to the domains, the highest score 
was observed in the domains of Provider Trust 
(88.81 ± 19.3), then, Medication Worries (69.40 ± 
33.27) and Overall Function (69.28 ± 27.75). The 
domains of HIV Mastery (61.67 ± 39.98), Life 
Satisfaction (59.07 ± 15.33) and Sexual Function 
(55.67 ± 41.17) had the moderate score, while 
the low scores were observed in the domains of 
Financial Worries (38.67 ± 22.14), Disclosure 
Worries (34.75 ± 28.73) and Health Worries 
(30.36 ± 21.03). 
 
After categorising the overall HRQoL scores, the 
frequency and percentage of the patients with 
Low HRQoL, Moderate HRQoL and High HRQoL 
were, 286 (33.4 %), 282 (32.9 %) and 289 (33.7 
%) respectively. Chi-square showed that there 
was no significant difference between the 
frequencies of the three categories. 
 
Distribution of WHO-recommended ART 
regimens used in the facility 
 
The frequency and percentage of each WHO-
recommended antiretroviral regimen used in the 
facility is shown in Table 3. Zidovudine (AZT) + 
lamivudine (3TC) + nevirapine (NVP) regimen 
(479) account for 54.9 %, most of the 
antiretroviral regimen used in the facility. 
Followed by tenofovir (TDF) + lamivudine (3TC) 
+ efavirenz (EFZ) regimen (212) which account 
for 24.3%. Among the second-line regimens 
however, the most common were tenofovir + 
lamivudine + lopinavir-ritonavir (LPV/r) 27 (3.1 
%), followed by tenofovir + lamivudine + 
atazanavir-ritonavir (ATV/r) 13 (1.5 %) and 
tenofovir + emtricitabine (FTC) + lopinavir-
ritonavir regimen 12 (1.4 %). Abacavir (ABC)-
based regimens were only used by five (0.5%) 
patients. Chi-Square test shows that there was a 
significant difference in the distribution of the 
regimens. 
 
HRQoL of patients taking WHO-recom-
mended ART regimen  
 
The result, on Table 3, showed that patients on 
tenofovir + emtricitabine + lopinavir-ritonavir 
regimen reported the highest HRQoL (67.58 ± 
14.80), followed by the patients on abacavir + 
lamivudine + nevirapine regimen, having 
reported 65.40 ± 9.40 score. However, among 
the two most utilised regimens, zidovudine + 
lamivudine + nevirapine and tenofovir + 
lamivudine + efavirenz, patients on the later 
reported higher HRQoL score of 64.41 ± 18.04 
than those on the former whose HRQoL score 
was 58.14 ± 18.53. Lowest scores were reported 
by patients on zidovudine + lamivudine + 
atazanavir-ritonavir and zidovudine + lamivudine 
+ lopinavir-ritonavir with the HRQoL scores of 
46.15 ± 20.66 and 44.11 ± 17.41 respectively. 
Patients on the other regimens reported 
moderate HRQoL scores. 
 
The study showed that the difference between 
the mean overall HRQoL score of the patients on 
the two most utilised regimens (zidovudine +  
lamivudine + nevirapine and tenofovir + 
lamivudine + efavirenz) was statistically 
significant (p = 0.0001) at 95 % confidence 
interval. 
 
Comparison was made between the domains 
HRQoL scores of the patients on each regimen. 
It was observed that there was significance 
difference in their HRQoL scores. In the two most 
utilised regimens, patients on tenofovir + 
lamivudine + efavirenz regimen reported a higher 
HRQoL score than their counterparts on 
zidovudine + lamivudine + nevirapine in all the 
domains except life satisfaction. Patients on 
tenofovir + emtricitabine + lopinavir-ritonavir, a 
second-line regimen, were better than patients 





The result of this study showed that patients in 
the facility reported a moderate HRQoL score. 
Financial Worries, Disclosure Worries and Health 
Worries were the problems worsening the 
HRQoL of the patients in this facility. The two 
most utilised regimens were AZT + 3TC + NVP 
and TDF + 3TC + EFZ. Patients on the later, just 
like those on other tenofovir-based regimens 
reported a significantly better HRQoL scores.  
 
From the findings of this study, the overall 
HRQoL score of the patients in this facility 
suggests that patients in this facility were 
averagely doing well with their therapy. The 
domain scores were high in Provider Trust, 
Medication Worries and Overall Function. This 
could indicate that the patients in this facility do 
receive a good relationship, care plan and 
education from their care providers which 
translates to them having less worries about their 
medication and thus, having a very good overall 
function. Cunningham et al in US, found that 
Physical HRQoL domain (in this case, Overall 
Function domain) was associated with good 
prognosis of HIV/AIDS [5]. In another study, 
Physical domain was among the domains having 
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the highest score [22]. Thus, this finding is 
consistent with the results of these studies. 
 
Similarly, the findings of Oparah et al suggest 
that the evaluated PLWHA reported good 
HRQoL in all the domains except the domain of 
Disclosure Worries [11]. This is unlike the 
findings of this study where in three domains 
(Financial Worries, Disclosure Worries, and 
Health Worries), low HRQoL scores were 
reported. However, just like their findings low 
score was also seen in the domain of Disclosure 
Worries. This could be due to the discrimination 
among Nigerians leaving with HIV/AIDS. The low 
score in the domain of Financial Worries could 
indicate the level of poverty among the patients 
in this facility. In this study, it was found that 41.7 
% of the patients earn less than $50.00 per 
month, another 49.4% of them earn between 
$50.00 to $250.00 per month. The poor score in 
the domain of Health Worries could be the 
reflection of the psychological effects of the 
perception of worse health related outcomes 
normally suffered by PLWHA. 
 
In this facility, it was found out that zidovudine + 
lamivudine + nevirapine regimen was the most 
utilised/used regimen, followed by tenofovir + 
lamivudine + efavirenz, among the first-line 
regimens. This may be due to their 
recommendation by WHO as alternative and 
preferred regimens, respectively [23]. Among the 
second-line regimens, tenofovir + lamivudine + 
lopinavir-ritonavir followed by tenofovir + 
lamivudine + atazanavir-ritonavir and tenofovir + 
emtricitabine + lopinavir-ritonavir were the most 
utilised regimens. Since the second-line 
regimens are reserved for patients that failed the 
first-line regimen, their distribution may be 
related to the availability, good health outcome, 
provider’s or patient’s preference. Abacavir-
based regimen were used by few patients, which 
may be because the WHO recommended that 
the regimen should be reserved for patients that 
may not be able to use the ‘preferred’ and 
‘alternative’ regimens [23].  
 
From the results, the patients showing the 
highest HRQoL score were those on tenofovir + 
emtricitabine + lopinavir-ritonavir, a second-line 
regimen. This could be preferred when switching 
patients to second line regimen. Patients on 
abacavir + lamivudine + nevirapine showed the 
second highest HRQoL score, but the group was 
represented by only three patients, hence, it has 
a very weak statistical power to be 
recommended as a preferred regimen. 
 
Among the two most utilised regimens in the 
facility, patients on tenofovir + lamivudine + 
efavirenz showed a significantly higher HRQoL 
score that could suggest that it will be more 
preferable than zidovudine + lamivudine + 
nevirapine  regimen.  It has  better  HRQoL  in all 
 
Table 2: Sociodemographic and HIV-related clinical 
characteristics of the patients (N = 872) 
 
Variable  Frequency 
(%) 
Gender  
 Female  651 (75.9) 
 Male 207 (24.1) 
Level of education  
 No formal education 254 (29.8) 
 Primary education 155 (18.2) 
 Secondary education 217 (25.4) 
 Post-secondary education 227 (26.6) 
Marital status  
 Single 138 (17.5) 
 Married 471 (59.8) 
 Widowed 136 (17.3) 
 Separated 43   (5.5) 
Monthly income (USD)  
 Less than 50.00 270 (41.7) 
 >50.00 to 250.00 320 (49.4) 
 >250.00 to 500.00 40   (6.2) 
 >500.00 18   (2.8) 
Occupation  
 Student 96   (15.8) 
 Self employed 338 (55.8) 
 Employee 161 (26.6) 
 Retired 11   (1.8) 
Residential arrangement  
 Lives alone 42   (5.0) 
 Lives with family 756 (90.5) 
 Lives with care-giver 37   (4.5) 
Smoking status  
 Non-smoker 681 (89.1) 
 Current smoker 83   (10.9) 
Engagement in physical activities  
 Do not engage  114 (13.3) 
 Do engage  741 (86.7) 
Current WHO clinical stage  
 Stage 1 451 (58.4) 
 Stage 2 307 (39.8) 
 Stage 3 13   (1.7) 
 Stage 4 1     (0.1) 
Adherence to ARV medication  
 Less than 95% 81   (16) 
 Greater than 95% 425 (84) 
Family size and age of the patients  
 Family size 7.06±5.72 
 Age 35.68±9.41 
Years of HIV diagnosis 5.25±3.07 
Number of years on ART 4.93±3.00 
Number of years on the current ART 
regimen 
3.83±2.43 
CD4 count (within the last 3 months) 
(cells/µl) 
458.59±258.3 
Current body weight (kg) 64.30±14.48 
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AZT+3TC+NVP 479 (54.9) 66.79 59.47 29.60 37.34 67.11 60.26 33.07 87.82 56.25 58.14±18.53* 
AZT+3TC+EFZ 34 (3.9) 69.24 59.71 23.18 34.71 72.00 54.58 30.46 84.31 51.84 56.37±19.80 
TDF+3TC+NVP 35 (4.0) 65.79 54.69 35.31 39.84 71.32 68.75 36.52 83.59 62.12 58.33±16.88 
TDF+3TC+EFZ 212 (24.3) 76.26 58.84 33.67 42.71 76.84 68.59 42.24 92.30 56.74 64.41±18.04* 
TDF+FTC+NVP 8 (0.9) 66.41 57.50 24.38 38.58 74.29 43.75 11.25 86.45 46.88 51.30±19.24 
TDF+FTC+EFZ 32 (3.7) 70.43 60.97 34.06 43.57 67.03 49.58 35.31 91.04 41.41 60.52±19.17 
AZT+3TC+LPV/r 10 (1.1) 51.40 57.22 22.78 29.19 37.22 34.38 11.67 82.41 40.63 44.11±17.41 
TDF+3TC+LPV/r 27 (3.1) 72.44 59.58 23.20 33.35 65.37 54.33 30.00 86.42 61.11 55.56±22.39 
TDF+FTC+LPV/r 12 (1.4) 83.33 60.83 34.17 46.63 77.92 77.68 31.25 91.67 55.21 67.58±14.80 
AZT+3TC+ATV/r 4 (0.5) 49.98 55.00 22.50 33.37 43.75 37.50 18.75 85.43 34.38 46.15±20.66 
TDF+3TC+ATV/r 13 (1.5) 63.15 55.00 23.46 30.39 56.92 63.54 22.50 94.23 53.13 52.09±11.44 
TDF+FTC+ATV/r 1 (0.1) 16.70 55.00 25.00 18.80 90.00 100.00 50.00 100.00 0.00 54.40±00.00 
ABC+3TC+NVP 3 (0.3) 77.10 32.50 45.00 37.55 52.50 62.50 42.50 83.35 87.50 57.37±19.51 














*Significant difference in their mean HRQoL scores using independent sample T-test at p < 0.05; a Significand difference in their frequency using Chi Square test at p < 0.05; 
AZT (Zidovudine), 3TC (Lamivudine), NVP (Nevirapine), EFZ (Efavirenz), TDF (Tenofovir), FTC (Emtricitabine), LPV/r (Lopinavir/Ritonavir), ATV/r (Atazanavir/Ritonavir), ABC 
(Abacavir) 
 




the domains except the domain of Life 
Satisfaction. Its higher score in the domain of 
HIV medication may be, in addition to other 
possible reasons, related to its once daily dosing, 
hence preferred by patients. 
 
WHO recommended that the preferred first-line 
antiretroviral regimen for adults (including 
pregnant and breastfeeding women and people 
with TB and HBV co-infection) is tenofovir + 
lamivudine (or emtricitabine) + efavirenz. 
Furthermore, the recommended alternative 
regimen is zidovudine + lamivudine + efavirenz 
(or nevirapine) or tenofovir + lamivudine (or 
emtricitabine) + nevirapine [23]. The 
recommendation is due to some clinical evidence 
with the aim of simplifying the regimens, 
preferably to once daily dosing and reducing the 
number of preferred regimens. These would 
provide a clinical, operational and programmatic 
benefits. This recommendation, according to 
WHO, is strong but with moderate-quality 
evidence. The finding of this study is in line with 
the WHO recommendation and could add to its 
moderate-quality evidence for their 
recommendation. 
 
Another first-line regimen that is preferred by the 
WHO is tenofovir + emtricitabine + efavirenz 
which also was, according to this study, 
associated with higher HRQoL score than the 
score of patients on other alternative first-line 
regimens. The difference offered by this regimen 
compared to other alternative regimens was not 
statistically significant, which was due to its 
smaller sample size [24], but clinically significant, 
because the difference might matter a lot to 
patients [24,25]. 
 
Moreover, with the exception of abacavir-based 
regimen (that has weak number for statistical 
comparison with other regimens), only the 
patients on Tenofovir-based regimen had up to 
60.0 of the overall HRQoL score which could 
indicate the possibility of tenofovir-based 
regimens being the better regimens. 
 
Similar studies that evaluated the HRQoL of 
patients taking different ARV regimens appear to 
be rare. Campo et al observed that Efavirenz-
based ARV regimens improves QoL, treatment 
satisfaction and adherence with low rates of 
virological failure in virologically suppressed 
patients taking protease inhibitor-based regimens 
[10]. In this study, out of the 6 groups patients 
each on different protease inhibitor-based 
regimens, only those on tenofovir + emtricitabine 
+ lopinavir-ritonavir reported a higher HRQoL 
than any of the 3 groups of patients on different 
efavirenz-based regimen.  
 
In some studies, however, clinical outcomes of 
patients on some ART were studied. Some of the 
findings are similar to those reported here 
despite the difference in the outcome 
parameters. In a systematic review and meta-
analysis, it was reported that nevirapine-based 
regimens were associated with more adverse 
effects and treatment discontinuation than 
efavirenz-based regimens [16]. Similarly, 
efavirenze-based regimens were reported to be 
less likely to cause virologic failure compared to 
nevirapine-based regimens [17]. This might be 
an additional reason why the WHO consider 
nevirapine among the combinations for 
alternative regimen. This could also be the 
reason why in this study, only the patients on one 
Efavirenz-based regimen (zidovudine + 
lamivudine + efavirenz) reported a HRQoL score 
that is lower than that of some patients on 
nevirapine-based regimens. However, all 
patients on other efavirenz-based regimens 
reported higher scores. 
 
In addition to better outcomes of efavirenz-based 
regimens, other studies reported a better 
outcomes of tenofovir-based regimens compared 
to that of other first-line ARV regimens. Patients 
on tenofovir were reported to have better 
improvement in survival and cost-effectiveness 
than those patients on stavudine and zidovudine 
[13]. Amoroso, et al. found out that patients on 
tenofovir + lamivudine (or emtricitabine) + 
efavirenz were better in terms of clinical 
outcomes than those on tenofovir + lamivudine 
(or emtricitabine) + nevirapine or others on 
zidovudine + lamivudine + nevirapine (or 
efavirenz)  [15]. On the contrary, patients on 
tenofovir + emtricitabine/lamivudine + nevirapine 
were found to be associated with higher mortality 
compared to those on zidovudine + lamivudine + 
nevirapine although this finding was not 
consistent across sensitivity analyses [14]. 
 
The findings of most other studies discussed 
indicated the superiority of Tenofovir- and 
Efavirenz-based first-line antiretroviral regimens. 
These findings, just as observed in this study and 
recommended by WHO, could suggest that 
tenofovir + lamivudine (or emtricitabine) + 
efavirenz regimens are the prefered first-line 
antiretroviral regimens. 
 
Limitations of the study 
 
The HRQoL outcome of patients over time was 
not evaluated in this study, because the study 
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was cross-sectional. A longitudinal survey could 
have taken care of that. 
 
Also, convenient sampling technique was used in 





Patients taking different ARV regimen in this 
facility reported a moderate HRQoL. The HRQoL 
scores in aspects of provider trust and 
medication worries were low. Zidovudine + 
lamivudine + nevirapine and tenofovir + 
lamivudine + efavirenz regimens were the most 
utilised regimen in the facility. Among patients on 
first-line regimens, those on tenofovir + 
lamivudine + efavirenz, followed by tenofovir + 
emtricitabine + efavirenz reported the highest 
HRQoL. On the other hand, among patients on 
second-line regimens, those on tenofovir + 
emtricitabine + lopinavir-ritonavir reported the 
best HRQoL outcomes.This finding could guide 
the choice of clinicians and other decision 
makers in selecting antiretroviral regimen for 
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